Literature DB >> 4378413

Direct evidence for Hageman factor (factor XII) activation by bacterial lipopolysaccharides (endotoxins).

D C Morrison, C G Cochrane.   

Abstract

Purified precursor Hageman factor has been demonstrated to bind to soluble bacterial lipopolysaccharide (LPS, endotoxin) isolated from Escherichia coli 0111:B4, and this complex has been shown to have the capacity to convert prekallikrein to its active form. In addition, LPS-activated Hageman factor substantially reduces clotting times in XII-deficient plasma. The capacity to activate Hageman factor has been demonstrated to reside in the lipid A region of the LPS molecule. Activation of Hageman factor by LPS contrasts with fluid-phase activation (e.g., by kallikrein or trypsin) in that no cleavage to lower molecular weight fragments occurs. High concentrations of LPS inhibit the activity of Hageman factor, probably by a direct LPS-Hageman factor interaction.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4378413      PMCID: PMC2139619          DOI: 10.1084/jem.140.3.797

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  25 in total

1.  ACTINOMYCIN SENSITIVITY IN ESCHERICHIA COLI PRODUCED BY EDTA.

Authors:  L LEIVE
Journal:  Biochem Biophys Res Commun       Date:  1965-01-04       Impact factor: 3.575

2.  Activation of Hagemen Factor by saturated fatty acids.

Authors:  J MARGOLIS
Journal:  Aust J Exp Biol Med Sci       Date:  1962-12

3.  The Origin of the Epithelioid Cell in Experimental Tuberculosis of the Cornea.

Authors:  E R Long; S W Holley
Journal:  Am J Pathol       Date:  1933-05       Impact factor: 4.307

4.  Anticomplementary activity of lipid A isolated from lipopolysaccharides.

Authors:  D C Morrison; P Verroust; W O Weigle
Journal:  Proc Soc Exp Biol Med       Date:  1973-09

5.  A method of trace iodination of proteins for immunologic studies.

Authors:  P J McConahey; F J Dixon
Journal:  Int Arch Allergy Appl Immunol       Date:  1966

6.  Chemical, physical, biological properties of a lipopolysaccharide from Escherichia coli K-235.

Authors:  F C McIntire; H W Sievert; G H Barlow; R A Finley; A Y Lee
Journal:  Biochemistry       Date:  1967-08       Impact factor: 3.162

7.  Activation of Hageman factor by ellagic acid and the generalized Shwartzman reaction.

Authors:  D G McKay; G Müller-Berghaus; V Cruse
Journal:  Am J Pathol       Date:  1969-03       Impact factor: 4.307

8.  Consumption of Hageman factor activity in the generalized Shwartzman reaction induced by liquoid. Its prevention by inhibition of Hageman factor activation.

Authors:  G Müller-Berghaus; H G Lasch
Journal:  Thromb Diath Haemorrh       Date:  1970-05-31

9.  Endotoxin-induced intravascular clotting: the need for granulocytes.

Authors:  R G Lerner; S I Rapaport; J M Spitzer
Journal:  Thromb Diath Haemorrh       Date:  1968-12-31

10.  A new method for the extraction of R lipopolysaccharides.

Authors:  C Galanos; O Lüderitz; O Westphal
Journal:  Eur J Biochem       Date:  1969-06
View more
  52 in total

Review 1.  FXII.

Authors:  G Fuhrer; M J Gallimore; W Heller; H E Hoffmeister
Journal:  Blut       Date:  1990-11

Review 2.  Bradykinin formation. Plasma and tissue pathways and cellular interactions.

Authors:  A P Kaplan; K Joseph; Y Shibayama; Y Nakazawa; B Ghebrehiwet; S Reddigari; M Silverberg
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

Review 3.  Update on meningococcal disease with emphasis on pathogenesis and clinical management.

Authors:  M van Deuren; P Brandtzaeg; J W van der Meer
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

Review 4.  Thrombosis as an intravascular effector of innate immunity.

Authors:  Bernd Engelmann; Steffen Massberg
Journal:  Nat Rev Immunol       Date:  2012-12-07       Impact factor: 53.106

5.  Influence of fine structure of lipid A on Limulus amebocyte lysate clotting and toxic activities.

Authors:  K Takayama; N Qureshi; C R Raetz; E Ribi; J Peterson; J L Cantrell; F C Pearson; J Wiggins; A G Johnson
Journal:  Infect Immun       Date:  1984-08       Impact factor: 3.441

6.  Ability of gonococcal and meningococcal lipooligosaccharides to clot Limulus amebocyte lysate.

Authors:  R I Roth; R Yamasaki; R E Mandrell; J M Griffiss
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

7.  Mechanisms involved in protection provided by immunization against core lipopolysaccharides of Escherichia coli J5 from lethal Haemophilus pleuropneumoniae infections in swine.

Authors:  B W Fenwick; J S Cullor; B I Osburn; H J Olander
Journal:  Infect Immun       Date:  1986-08       Impact factor: 3.441

8.  Resistance of C3H/HeJ mice to the effects of Haemophilus pleuropneumoniae.

Authors:  B W Fenwick; B I Osburn; H J Olander
Journal:  Infect Immun       Date:  1986-09       Impact factor: 3.441

9.  Structural features of Salmonella typhimurium lipopolysaccharide required for activation of tissue factor in human mononuclear cells.

Authors:  F R Rickles; P D Rick
Journal:  J Clin Invest       Date:  1977-06       Impact factor: 14.808

10.  Antithrombin III metabolism in patients with liver disease.

Authors:  E Knot; J W Ten Cate; H R Drijfhout; L H Kahlé; G N Tytgat
Journal:  J Clin Pathol       Date:  1984-05       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.